Medscape is available in 5 Language Editions – Choose your Edition here.


Alpha1-Antitrypsin Deficiency Treatment & Management

  • Author: Dora E Izaguirre, MD; Chief Editor: Ryland P Byrd, Jr, MD  more...
Updated: Sep 24, 2014

Medical Care

Preventing or slowing the progression of lung disease is the major goal of alpha1-antitrypsin deficiency (AATD) management. Decreasing any proinflammatory stimuli in the alveolus, including smoking, asthma, or respiratory infection, facilitates this goal. Alternatively, augmenting or replacing the deficient enzyme, and thereby moderating inflammatory stimuli, is possible. Most patients are identified only after they develop lung disease, and the goals of treating AATD emphysema are similar to those for treating all forms of emphysema.

To decrease the risk of liver disease, vaccination against hepatitis A and B is recommended.

Quitting smoking

No treatment for emphysema has a greater effect on survival than quitting smoking.

Make a concerted effort to inform patients about the serious consequences of smoking on AATD and provide them with one of the many aids to help them quit.

Remember the 4 stages in the process of helping patients become nonsmokers: (1) ask about smoking habits; (2) advise about health effects; (3) assist the patient with encouragement, education, and nicotine replacement; and (4) arrange follow-up.

Most patients with AATD quit successfully.

Improving lung function

Provide similar efforts to improve lung function in patients with AATD emphysema as those provided to patients with emphysema from the usual causes.

Administer short-acting beta-adrenergic agents and ipratropium bromide bronchodilators to maximize lung function. Metered-dose inhalers are the preferred method of administration because they have a lower incidence of adverse effects than other routes. No matter how they are administered, no evidence indicates that these drugs have any long-term effect on disease progression.

Inhaled corticosteroids have not been studied in patients with AATD emphysema, but many patients have significant bronchoreactivity. In this group, inhaled steroids probably help control symptoms. Patients with frequent exacerbations may also benefit.

Long-acting inhaled beta-adrenergic drugs and anticholinergics provide improved bronchodilation and symptoms for patients with COPD. They have not been studied in a population with AATD, but they are likely to provide the same benefits.

Reserve oral corticosteroids for acute exacerbations with increased cough and sputum. Long-term administration of corticosteroids does not protect the lung from progressive emphysema, but it is associated with many detrimental adverse effects. Limit oral steroid use to brief courses of 1-2 weeks. Start therapy to prevent osteoporosis when long courses are administered.

Theophylline may lessen the degree of dyspnea in some individuals, and a therapeutic trial may be indicated for selected patients. The therapeutic range of theophylline is relatively small, and its metabolism frequently is altered by other drugs or illness, which can lead to frequent episodes of drug toxicity or the need for frequent monitoring of serum levels.

Preventing respiratory infections

Pneumonia and annual influenza vaccines will help prevent respiratory infections.

The ATS/ERS AAT Deficiency Task Force recommends early antibiotic therapy for all exacerbations with purulent sputum. Aggressively treatment of infections may help decrease the potential for additional lung injury from an influx of neutrophils into the alveolus.

Providing pulmonary rehabilitation

According to a National Institutes of Health (NIH) workshop, pulmonary rehabilitation is defined as "a multi-disciplinary continuum of services directed to persons with pulmonary disease and their families, usually by an interdisciplinary team of specialists, with the goal of achieving and maintaining the individual's maximum level of independence and function in the community."

Most programs combine education, exercise conditioning, breathing training, chest physical therapy, and respiratory muscle training with nutritional counseling and psychological support.

Therapy does not improve pulmonary function test results, but well-controlled studies document significant improvement in exercise endurance, exercise work capacity, level of dyspnea, quality of life, and reduction of health-related expenses.

Reducing hypoxemia

Hypoxemia accelerates mortality in patients with severe airflow obstruction, and oxygen supplementation prolongs survival for this group.

Oxygen also increases exercise capacity, improves mental performance, decreases dyspnea with exercise, and improves sleep quality.

Stable patients with resting hypoxia benefit most if they wear their oxygen mask continuously. The benefits for patients with hypoxemia only during exercise or sleep are not as clear, and oxygen may be prescribed for those intervals when the oxygen saturation is likely to be low.

Replacing enzymes

Alpha1-antitrypsin-deficient individuals who have or show signs of developing significant emphysema can be treated with Prolastin, a pooled, purified, human plasma protein concentrate replacement for the missing enzyme that has been screened for HIV and hepatitis viruses, although practitioners should immunize patients against hepatitis regardless. It also is heat-treated as an additional precaution against transmission of infection. The US Food and Drug Administration (FDA) has approved 2 other alpha1-antitrypsin protein concentrates, Aralast and Zemaira, for augmentation therapy.

Weekly IV infusions of alpha1-antitrypsin protein concentrates restore serum and alveolar alpha1-antitrypsin concentrations to protective levels. Although other dosing regimens have been used, only the weekly infusion schedule has US FDA approval.

No controlled studies have proven that IV augmentation therapy improves survival or slows the rate of emphysema progression. Results from the NIH patient registry and a comparison of Danish and German registries have been published, and both suggest that augmentation therapy has beneficial effects. Although they were not controlled treatment trials, the similarity of the results suggests that the findings are significant.

The NIH report described an overall death rate 1.5 times higher for those who did not receive augmentation therapy and a rate of FEV1 decline (54 mL/y) in alpha1-antitrypsin-deficient individuals, about twice that of healthy nonsmokers but about 50% that of smokers (108 mL/y). Prolastin augmentation therapy did not improve the average FEV1 decline (54 mL/y); however, participants with moderate airflow obstruction (FEV1 35-60% of predicted value) had a slower rate of decline (mean difference 27 mL/y).

These findings bolster the long-held belief that augmentation therapy provides clinical benefit. Studies of Aralast and Zemaira have shown equivalency with Prolastin in achieving and maintaining alpha1-antitrypsin serum levels and alveolar epithelial levels above the target level. No studies of Aralast or Zemaira have been done to show effects on FEV1, rate of decline of FEV1, or survival.

Current guidelines recommend augmentation therapy for individuals with abnormal alpha1-antitrypsin genotypes who have alpha1-antitrypsin levels below 11 μM and documented evidence of airflow obstruction in pulmonary function tests.[13, 12]

While no firm guidelines have been developed for initiating or continuing augmentation therapy, most pulmonary physicians require the serum level to be below the threshold protective value and that the patient have one or more of the following: signs of significant lung disease: chronic productive cough or unusual frequency of lower respiratory infection, airflow obstruction, accelerated decline of FEV1, or chest radiographic or CT evidence of emphysema.

The ATS recommends starting treatment when the FEV1 is less than 80% of the patient's predicted value, though the benefits of augmentation therapy for individuals with severe (FEV1 < 35%) or mild (FEV1 >60%) airflow obstruction are less, as shown in studies with Prolastin.

Evidence for the use of alpha1-antitrypsin augmentation in patients after lung transplantation for alpha1-antitrypsin deficiency is insufficient. However, observational studies do show that inflammation from acute rejection or infection allows for free elastase activity in the epithelial lining fluid of individuals who have undergone lung transplantation. Therefore, the ATS/ERS Task Force favors the use of augmentation therapy for lung transplant recipients during episodes that provoke inflammation.

A 2008 commentary by the authors of the Medical and Scientific Advisory Committee of the Alpha-1 Foundation regarding the use of augmentation therapy for PI*MZ heterozygotes states that currently, until supportive data in the subset of heterozygotes becomes available, the only approved use for augmentation therapy is for PiZZ individuals.[15]

The Canadian Thoracic Society recommends the use of augmentation therapy in nonsmoking or smoking individuals with COPD attributable to emphysema and documented AATD who are receiving optimal and pharmacological and nonpharmacological therapy.

Other potential therapies

Several manufacturers are testing alternative routes of administration of current augmentation medications. Although IV replacement therapy shows promise in delaying progression the disease, it has the disadvantage that only 2% of the administered drug reaches the lungs. In addition, IV replacement requires weekly visits for treatment. Testing is now underway to investigate direct application of Prolastin in the lungs by inhalation. With commercial inhalation devices and deep slow inhalation, peripheral deposition of approximately 60% of aerosolized drug can be achieved. Further randomized, blinded, controlled efficacy studies are needed, though the small doses and ease of administration make inhalation therapy an attractive option.

Some manufacturers are investigating alternative sources of augmentation therapy particularly given concerns related to the limited supply of the pooled human plasma and the potential for transmission of infectious agents. Transgenic production of human alpha1-antitrypsin protein has been accomplished in sheep and goats. Recombinant technology has also been used to produce human alpha1-antitrypsin in yeast. Unfortunately, because of differences in the glycosylation of the alpha1-antitrypsin protein in the different species, these proteins are cleared rapidly from human circulation; therefore, IV administration is difficult. However, such transgenic or recombinant sources could be used in inhalation devices.

Other investigations have targeted the emphysematous changes in the lungs. Studies with elastase induced emphysema in rats suggested that administration of all-trans retinoic acid (ATRA) caused reversal of the emphysematous changes due to stimulation of growth of new alveoli by ATRA. Other trials are testing hyaluronic acid as individuals with emphysema have been noted to have reduced levels of hyaluronic acid in their lungs. Last, investigators are considering antioxidants, such as vitamins A, C and/or E, as potential treatments for emphysema.

The most common alpha1-antitrypsin genetic defects prevent release of the protein from hepatocytes because of inappropriate polymerization and folding. Some investigators are testing processes or medications that could promote release from the liver cells. Synthetic chaperones, such a 4-phenyl-butyric acid (4-PBA), have been used in cystic fibrosis and are being studied in alpha1-antitrypsin deficiency. Initial results show modest increases in serum alpha1-antitrypsin levels, and GI adverse effects can be dose limiting. Work is being done on molecular interventions, such as the introduction of small peptides that fit into the abnormal alpha1-antitrypsin molecule at the site where abnormal folding begins. Other approaches are to replace specific amino-acid targets in the folding site to prevent abnormal folding.

Insertion of a normal human alpha1-antitrypsin gene has been done in muscle and liver cells. Gene-repair technologies are also being studied, as are attempts to turn off production of the abnormal gene product.


Surgical Care

Two surgical approaches may help selected patients with emphysema due AATD.

Volume-reduction surgery

Volume-reduction surgery has generated nationwide interest and hope for patients with all types of emphysema.[16]

Selected patients with severe emphysema and significant air trapping have experienced symptomatic improvement by removing the most severely affected 20-35% of each lung. Spirometry and exercise tolerance generally improve following postoperative recovery. Dyspnea generally is diminished. The effects on blood gas values are variable.

Some of the enthusiasm for the procedure has waned, even as surgical mortality rates have diminished, because the duration of improvement seems to be brief; an accelerated rate of FEV1 decline appears to occur after the surgery.

The randomized controlled National Emphysema Treatment Trial showed benefit to only those with poor exercise tolerance and predominantly upper lobe disease. Others with diffuse disease, basilar disease, and/or good exercise tolerance did not benefit from lung-volume reduction. In some instances, mortality was increased. This study included patients with emphysema of all etiologies.

A small prospective study of 21 patients with alpha1-antitrypsin deficiency showed improvement in the mean dyspnea score at 3 months after surgery. This finding persisted for as long as 3.5 years. Improvements were also noted in mean FEV1, vital capacity, and the ratio of residual volume to total lung capacity; these results persisted for 1-2 years. Patients with heterogeneous emphysema with little or no inflammatory airway disease appeared to benefit most. Overall, changes in patients with advanced emphysema from alpha1-antitrypsin deficiency were inferior to those changes in patients with smoking-related emphysema, as they were decreased in magnitude and duration.

Lung transplantation

If patients are at substantial risk of early mortality and are otherwise healthy, they may be candidates for lung transplantation.

Contact a local transplant center before patients become too ill (cachexia, inactivity, frequent infections). With a recent change in the system for allocation of lungs for transplantation, patients with emphysema are being more carefully evaluated for listing. Many transplant programs have adopted the BODE index to identify patients with emphysema who are most likely to benefit from transplantation. The uncertainties of emphysema exacerbations and complications that might prevent transplantation make it imperative that patients be referred when their BODE index is 5-6 or if they have experienced an episode of acute hypercapnic respiratory failure.[17]

Liver transplantation

Liver transplantation is the definitive treatment for advanced liver disease.[3]



The diagnosis of AATD emphysema is not difficult, but most physicians have no experience treating a patient, in determining the need for enzyme replacement, in providing counseling, or in answering the questions that this uncommon hereditary disorder generates. Consultation with a specialist offers answers to these and other needs.

The Alpha-1 National Association, 1-800-4ALPHA-1, can help in locating physicians with interest and experience in caring for these patients.

Several organizations have been created to provide support, education, advocacy, and links to ongoing research.



Patients with advanced COPD are characterized by a significant reduction in fat-free muscle mass. This pulmonary cachexia is common in patients with AATD and is associated with a decline in clinical status. The syndrome is a result of multiple factors, including hypermetabolism, drug therapy, inactivity, and aging. Prolonged glucocorticoid administration accelerates the process.

Protein-calorie supplementation, as one component of a comprehensive treatment program, may reverse the loss of muscle mass, and dietary counseling may aid patients at high nutritional risk. Adding fat-based nonprotein calories may benefit patients with respiratory failure who are receiving mechanical ventilation. However, other than this special circumstance, little evidence exists to suggest that this dietary manipulation aids ambulatory patients.



Dyspnea limits activity, which results in deconditioning and further reductions in activity levels. Encourage all patients with lung disease to maintain activity levels. Pulmonary rehabilitation programs and patient support groups are particularly helpful.

Contributor Information and Disclosures

Dora E Izaguirre, MD Primary Care Physician; Researcher, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Dora E Izaguirre, MD is a member of the following medical societies: American Heart Association, American Medical Association, American Public Health Association, Colegio Medico de Honduras

Disclosure: Nothing to disclose.


Klaus-Dieter Lessnau, MD, FCCP Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Jesus Lanza, MD Fellow in Pulmonary and Critical Care Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Ryland P Byrd, Jr, MD Professor of Medicine, Division of Pulmonary Disease and Critical Care Medicine, James H Quillen College of Medicine, East Tennessee State University

Ryland P Byrd, Jr, MD is a member of the following medical societies: American College of Chest Physicians, American Thoracic Society

Disclosure: Nothing to disclose.

Additional Contributors

Ryland P Byrd, Jr, MD Professor of Medicine, Division of Pulmonary Disease and Critical Care Medicine, James H Quillen College of Medicine, East Tennessee State University

Ryland P Byrd, Jr, MD is a member of the following medical societies: American College of Chest Physicians, American Thoracic Society

Disclosure: Nothing to disclose.


Paul Fairman, MD Director, Pulmonary Hypertension Service, Professor, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University

Paul Fairman, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Thoracic Society

Disclosure: Nothing to disclose.

Sarah Catherine Lyman Hellewell, MD Consulting Staff, Lynchburg Pulmonary Associates

Sarah Catherine Lyman Hellewell is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, and American Thoracic Society

Disclosure: Nothing to disclose.

Rajiv Malhotra, DO Assistant Professor, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Section of Interventional Pulmonary Medicine, Virginia Commonwealth University Health System

Rajiv Malhotra, DO is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Osteopathic Association

Disclosure: Nothing to disclose.

  1. Stoller JK, Aboussouan LS. A review of a1-antitrypsin deficiency. Am J Respir Crit Care Med. 2012 Feb 1. 185(3):246-59. [Medline].

  2. Stoller JK, Brantly M. The challenge of detecting alpha-1 antitrypsin deficiency. COPD. 2013 Mar. 10 Suppl 1:26-34. [Medline].

  3. Stoller JK, Lacbawan FL, Aboussouan LS. Alpha-1 Antitrypsin Deficiency. 1993. [Medline].

  4. Marciniuk DD, Hernandez P, Balter M, Bourbeau J, Chapman KR, Ford GT, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2012 Mar-Apr. 19(2):109-16. [Medline]. [Full Text].

  5. Greene DN, Elliott-Jelf MC, Straseski JA, Grenache DG. Facilitating the laboratory diagnosis of a1-antitrypsin deficiency. Am J Clin Pathol. 2013 Feb. 139(2):184-91. [Medline].

  6. Bornhorst JA, Greene DN, Ashwood ER, Grenache DG. a1-Antitrypsin phenotypes and associated serum protein concentrations in a large clinical population. Chest. 2013 Apr. 143(4):1000-8. [Medline].

  7. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest. 2005 Sep. 128(3):1179-86. [Medline].

  8. Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol. 2008 Aug. 103(8):2136-41; quiz 2142. [Medline].

  9. Petrache I, Fijalkowska I, Zhen L, Medler TR, Brown E, Cruz P, et al. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med. 2006 Jun 1. 173(11):1222-8. [Medline].

  10. Banauch GI, Brantly M, Izbicki G, et al. Accelerated spirometric decline in New York City firefighters with a1-antitrypsin deficiency. Chest. 2010 Nov. 138(5):1116-24. [Medline]. [Full Text].

  11. Odin JA, Kesar V. Alpha-1 antitrypsin deficiency. Ahmad J, Friedman SL, Dancygier H. Mount Sinai expert guides: hepatology. 1st ed. John Willey and Sons; 2014. 17. [Full Text].

  12. Campos MA, Lascano J. a1 Antitrypsin deficiency: current best practice in testing and augmentation therapy. Ther Adv Respir Dis. 2014 Jul 9. [Medline].

  13. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003 Oct 1. 168(7):818-900. [Medline].

  14. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4. 350(10):1005-12. [Medline].

  15. Sandhaus RA, Turino G, Stocks J, Strange C, Trapnell BC, Silverman EK, et al. alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. Chest. 2008 Oct. 134(4):831-4. [Medline].

  16. Tutic M, Bloch KE, Lardinois D, Brack T, Russi EW, Weder W. Long-term results after lung volume reduction surgery in patients with alpha1-antitrypsin deficiency. J Thorac Cardiovasc Surg. 2004 Sep. 128(3):408-13. [Medline].

  17. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006 Jul. 25(7):745-55. [Medline].

  18. Stoller JK, Tomashefski J Jr, Crystal RG, Arroliga A, Strange C, Killian DN. Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry. Chest. 2005 Apr. 127(4):1196-204. [Medline].

  19. Alpha-1-Antitrypsin Deficiency Registry Study. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1998 Jul. 158(1):49-59. [Medline].

  20. Brand P, Beckmann H, Maas Enriquez M, Meyer T, Müllinger B, Sommerer K, et al. Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices. Eur Respir J. 2003 Aug. 22(2):263-7. [Medline].

  21. Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis. 1988 Aug. 138(2):327-36. [Medline].

  22. Celli BR. Pulmonary rehabilitation for patients with advanced lung disease. Clin Chest Med. 1997 Sep. 18(3):521-34. [Medline].

  23. Fishman AP. Pulmonary rehabilitation research. Am J Respir Crit Care Med. 1994 Mar. 149(3 Pt 1):825-33. [Medline].

  24. Köhnlein T, Welte T. Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med. 2008 Jan. 121(1):3-9. [Medline].

  25. Sandhaus RA. alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency. Thorax. 2004 Oct. 59(10):904-9. [Medline].

  26. Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax. 1994 Jul. 49(7):695-8. [Medline].

  27. Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997 Oct. 10(10):2260-3. [Medline].

  28. Stockley RA. Alpha-1-antitrypsin deficiency: what next?. Thorax. 2000 Jul. 55(7):614-8. [Medline].

  29. Stoller JK, Aboussouan LS. alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding. Thorax. 2004 Aug. 59(8):708-12. [Medline].

  30. Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med. 1994 Nov-Dec. 61(6):461-7. [Medline].

  31. Sveger T, Piitulainen E, Arborelius M Jr. Lung function in adolescents with alpha 1-antitrypsin deficiency. Acta Paediatr. 1994 Nov. 83(11):1170-3. [Medline].

  32. Thelin T, Sveger T, McNeil TF. Primary prevention in a high-risk group: smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD). Acta Paediatr. 1996 Oct. 85(10):1207-12. [Medline].

Close-up chest radiograph of the right lower zone of a 39-year-old woman with alpha1-antitrypsin deficiency (AATD). Normal lung markings are absent in the costophrenic angle. Some lung markings are present in the pericardiac region, but even these are diminished.
CT scan of the right middle and right lower lobes in a 38-year-old patient with alpha1-antitrypsin deficiency (AATD). Entire middle lobe and much of the lower lobe are emphysematous; normal lung structures have been replaced by abnormal airspaces. Only the posterior portions of the right lower lobe maintain a normal architecture.
Graph outlines alpha1-antitrypsin levels and risk of lung disease for the 5 most common phenotypes of alpha1-antitrypsin deficiency (AATD). Dashed line at 11 mmol/L (80 mg/mL) represents the threshold level below which emphysema is common.
Breath sound assessment. Video courtesy of Therese Canares, MD, and Jonathan Valente, MD, Rhode Island Hospital, Brown University.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.